FDA Approves AVAPRO — Sanofi-Aventis U.S. LLC

SAINT-LEU-LO-D'ENFER, France – Sanofi lifecycle management activities bolstered by the FDA approval of IVIRBESARTAN are poised to extend the commercial life of the popular antihypertensive AVAPRO, potentially generating additional revenue streams as the market adapts to prevalent generic competition.